doi: 10.1007/BF01932371.
Antiparkinsonian drug doses and neuroleptic receptors
- PMID: 720482
- DOI: 10.1007/BF01932371
Item in Clipboard
Antiparkinsonian drug doses and neuroleptic receptors
Experientia.
.
Abstract
The clinical potency of 3 drugs, apomorphine, N-propylnorapomorphine, and bromocryptine, have been found to be closely correlated to their potencies in competing for 3H-haloperidol and 3H-spiroperidol both of which label the dopamine receptor. This correlation indicates that the direct binding assay may be used to predict clinical potencies of anti-parkinsonian drugs, and indicates that agonists as well as antagonists compete potently for 3H-neuroleptic binding.
Similar articles
-
Species variation in dopamine receptor binding.Eur J Pharmacol. 1979 Nov 23;60(1):55-66. doi: 10.1016/0014-2999(79)90052-9. Eur J Pharmacol. 1979. PMID: 520417
-
Characterization of dopamine autoreceptor and [3H]spiperone binding sites in vitro with classical and novel dopamine receptor agonists.Eur J Pharmacol. 1983 Mar 18;88(1):11-26. doi: 10.1016/0014-2999(83)90387-4. Eur J Pharmacol. 1983. PMID: 6133762
-
Multiple receptors for brain dopamine.Proc Natl Acad Sci U S A. 1978 Mar;75(3):1153-6. doi: 10.1073/pnas.75.3.1153. Proc Natl Acad Sci U S A. 1978. PMID: 418405 Free PMC article.
-
Binding of antiparkinsonian ergot derivatives to the dopamine receptor.Psychopharmacology (Berl). 1981;75(2):119-23. doi: 10.1007/BF00432172. Psychopharmacology (Berl). 1981. PMID: 6798600
-
Dopamine receptors in the central nervous system.Fed Proc. 1978 Feb;37(2):131-6. Fed Proc. 1978. PMID: 414936 Review.